Aripiprazole Tablet
Product Images NDC 50228-476

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50228-476). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Aripiprazole Figure1)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for Aripiprazole's AUC and Cmax when coadministered with various drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis represents change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic chart illustrating the effect of different drugs on Aripiprazole's dehydro- form fold change with 90% confidence intervals. The x-axis shows the change relative to a reference without an interacting drug, ranging from 0 to 3, while the y-axis categorizes drugs as CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). Data points indicate the changes in AUC and Cmax for each drug interaction.*

FDA Label Image

Figure 3 (Aripiprazole Figure3)

A graph titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs. The x-axis represents change relative to reference (without interacting drug) on a scale from 0.5 to 3.0. Drugs listed on the y-axis include dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, with pharmacokinetic parameters such as AUC, Cmax, DM, DRP, and INR noted. Data points indicating fold change with error bars are plotted for each drug parameter.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of Aripiprazole in special populations. The x-axis represents change relative to reference, ranging from 0.5 to 3.0. The y-axis lists populations: CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and renal impairment severity, with measurements for AUC and Cmax parameters for each group.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the change relative to reference for AUC and Cmax across variables including CYP2D6 metabolizer status, gender, age groups, and levels of hepatic and renal impairment. The chart displays fold change data with 90% confidence intervals for each factor affecting Aripiprazole metabolism.*

FDA Label Image

Figure 6 (Aripiprazole Figure6)

A Kaplan-Meier plot showing the proportion of subjects with relapse over time in days from randomization, comparing Aripiprazole and placebo groups. The graph includes a number of subjects at risk table below the x-axis corresponding to each time point for both groups.*

FDA Label Image

Figure 7 (Aripiprazole Figure7)

A Kaplan-Meier curve showing proportion with relapse over 182 days from randomization for Aripiprazole versus placebo. The y-axis shows proportion with relapse from 0 to 1; the x-axis shows days from randomization with numbers of subjects at risk below. The Aripiprazole line is lower than placebo, indicating fewer relapses over time.*

FDA Label Image

Figure 8 (Aripiprazole Figure8)

A line graph comparing the proportion with relapse over time between aripiprazole and placebo groups. The x-axis represents days from randomization, ranging up to 364 days, and the y-axis shows the proportion with relapse from 0 to 1. Two lines display relapse trends for aripiprazole (solid line) and placebo (dashed line), with a table indicating the number of subjects at risk at various time points for both groups.*

FDA Label Image

2mg-30 (Aripiprazole Label1)

Label for Aripiprazole Tablets, USP 2 mg oral tablets by ScieGen Pharmaceuticals Inc. The label indicates a bottle containing 30 tablets, marked Rx only, with instructions to dispense an enclosed medication guide. Storage and safety warnings are present, along with a barcode and manufacturer details in Hauppauge, NY.*

FDA Label Image

20mg-1000 (Aripiprazole Label10)

Label for Aripiprazole Tablets, USP 20 mg oral tablets by ScieGen Pharmaceuticals Inc. The label indicates a package size of 1,000 tablets with the NDC 50228-479-10. It includes storage instructions and a caution to keep out of reach of children, along with a barcode and manufacturer details.*

FDA Label Image

30mg-30 (Aripiprazole Label11)

Aripiprazole Tablets, USP label showing 30 mg strength. The label includes storage instructions to keep tablets in tightly closed containers at 25°C with permitted excursions between 15°C and 30°C. It states a package size of 30 tablets, Rx only, and is manufactured by ScieGen Pharmaceuticals, Inc. The label features a barcode and a note for pharmacists to dispense an enclosed Medication Guide.*

FDA Label Image

30mg-1000 (Aripiprazole Label121)

Aripiprazole Tablets, USP 30 mg oral tablets in a 1,000 tablet package. The label shows NDC 50228-480-10, manufacturer ScieGen Pharmaceuticals Inc with address in Hauppauge, NY. The label includes storage instructions, a pharmacist dispensing note, and a barcode.*

FDA Label Image

2mg-1000 (Aripiprazole Label2)

Label for Aripiprazole Tablets, USP 2 mg oral tablets by ScieGen Pharmaceuticals Inc. The label includes the NDC 50228-475-10, storage instructions, quantity of 1,000 tablets, and a barcode. It specifies pharmacist dispensing instructions and cautions to keep medication out of children’s reach.*

FDA Label Image

5mg-30 (Aripiprazole Label3)

Aripiprazole Tablets, USP 5 mg oral tablets, packaged in a container of 30 tablets labeled by ScieGen Pharmaceuticals Inc. The label includes storage instructions to keep tablets in tightly closed containers at 25°C with permitted excursions, dosage guidance to read prescribing information, and a barcode. The product is marked Rx Only.*

FDA Label Image

5mg-1000 (Aripiprazole Label4)

Label for Aripiprazole Tablets USP, 5 mg strength, manufactured by ScieGen Pharmaceuticals Inc. The label indicates a container size of 1,000 tablets and includes storage instructions, pharmacist dispensing advice, and a barcode. The label also notes the product is Rx only and provides space for lot and expiration dates.*

FDA Label Image

10mg-30 (Aripiprazole Label5)

Label for Aripiprazole Tablets, USP 10 mg oral tablets by ScieGen Pharmaceuticals Inc. The package contains 30 tablets. Storage instructions specify keeping tightly closed containers at 25°C (77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F). The label includes pharmacist instructions and a barcode.*

FDA Label Image

10mg-1000 (Aripiprazole Label6)

Aripiprazole Tablets USP 10 mg oral tablets label displaying the NDC 50228-477-10, with a package size of 1,000 tablets. The label includes storage instructions, pharmacist dispensing instructions, and manufacturer information for ScieGen Pharmaceuticals Inc, Hauppauge, NY. Barcode and lot/expiration placeholders are present.*

FDA Label Image

15mg-30 (Aripiprazole Label7)

Aripiprazole Tablets USP 15 mg oral tablets label by ScieGen Pharmaceuticals Inc. The label states the tablet strength as 15 mg, the package contains 30 tablets, and is prescription only. It includes storage instructions to keep tablets in tightly closed containers at 25°C with permitted excursions. The label features a barcode, manufacturer details, and a note for pharmacists to dispense the Medication Guide to patients.*

FDA Label Image

15mg-30 (Aripiprazole Label8)

Aripiprazole Tablets, USP 15 mg oral tablets label from ScieGen Pharmaceuticals Inc. The label includes storage instructions, pharmacist dispensing information, and a package count of 1,000 tablets. The label displays the NDC 50228-478-10 and states the tablets contain 15 mg of aripiprazole each. The manufacturer's name and address are also shown.*

FDA Label Image

20mg-30 (Aripiprazole Label9)

Label for Aripiprazole Tablets, USP 20 mg oral tablets manufactured by ScieGen Pharmaceuticals Inc. The label indicates a bottle containing 30 tablets, with storage instructions to keep tightly closed at controlled room temperature. It includes a barcode, NDC 50228-479-30, and a pharmacist instruction to dispense the enclosed Medication Guide.*

FDA Label Image

Aripiprazole-structure.jpeg (Aripiprazole Structure)

Chemical structure of aripiprazole, showing its molecular connectivity including dichlorophenyl and piperazine-related moieties, consistent with the active ingredient for the oral tablet form by ScieGen Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.